Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS) · Myelodysplastic Syndromes · Hematological Malignancies · B-cell Malignancy, Low-grade · Myelodysplastic Syndrome With Low-grade Lesions · IgG Monoclonal Gammopathy of Uncertain Significance · Smoldering Multiple Myeloma · Waldenstrom Macroglobulinemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Irene Ghobrial, MD)Dana Farber Cancer Institute at St. Elizabeth's, Brighton, Massachusetts, United States
Contact: Study coordinator (Joseph Grider)Contact: Principal Investigator (Olga Kozyreva, MD)Dana Farber Cancer Institute at Merrimack Valley, Methuen, Massachusetts, United States
Contact: Study coordinator (Saida Hussain)Contact: Principal Investigator (Pedro Sanz-Altamira, MD)Dana Farber Cancer Institute at Milford Regional Medical Center, Milford, Massachusetts, United States
Contact: Study coordinator (Laura Melancon)Contact: Principal Investigator (Michael Constantine, MD)Dana Farber Cancer Institute at South Shore, Weymouth, Massachusetts, United States
Contact: Study coordinator (Rebeka Lovato)Contact: Principal Investigator (Irene Ghobrial, MD)West Michigan Cancer Center, Kalamazoo, Michigan, United States
Contact: Principal Investigator (Mohammad Omaira, MD)Dana Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States
Contact: Study coordinator (Shannon Peabody)Contact: Principal Investigator (Jeanna Walsh, MD)
Study leads
Irene Ghobrial, MD
Principal Investigator
Dana-Farber Cancer Institute